Nagarajah, James
Radboud University Medical Center
5 papers on CoChatORCID 0000-0002-3555-0809
Most cited papers
- Verified
177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial
Morris, M. J., Castellano, D., Herrmann, K., de Bono, J. S., Shore, N. D., Chi, K. N., Crosby, M., Piulats, J. M., Fléchon, A., Wei, X. X., et al. (2024) · The Lancet
Prostate Cancer Treatment and ResearchRadiopharmaceutical Chemistry and Applications
Cited by 362
- Verified
Health-related quality of life and pain outcomes with [177Lu]Lu-PSMA-617 plus standard of care versus standard of care in patients with metastatic castration-resistant prostate cancer (VISION): a multicentre, open-label, randomised, phase 3 trial
Fizazi, K., Herrmann, K., Krause, B. J., Rahbar, K., Chi, K. N., Morris, M. J., Sartor, O., Tagawa, S. T., Kendi, A. T., Vogelzang, N., et al. (2023) · The Lancet Oncology
Prostate Cancer Treatment and ResearchRadiopharmaceutical Chemistry and Applications
Cited by 125
- Verified
EIF1AX and RAS Mutations Cooperate to Drive Thyroid Tumorigenesis through ATF4 and c-MYC
Krishnamoorthy, G. P., Davidson, N. R., Leach, S. D., Zhao, Z., Lowe, S. W., Lee, G., Landa, I., Nagarajah, J., Saqcena, M., Singh, K., et al. (2019) · Cancer Discovery
Thyroid Cancer Diagnosis and TreatmentRNA and protein synthesis mechanisms
Cited by 94
- Verified
Intra-therapeutic dosimetry of [177Lu]Lu-PSMA-617 in low-volume hormone-sensitive metastatic prostate cancer patients and correlation with treatment outcome
Peters, S. M. B., Privé, B. M., de Bakker, M., de Lange, F., Jentzen, W., Eek, A., Muselaers, C. H. J., Mehra, N., Witjes, J. A., Gotthardt, M., et al. (2022) · European Journal of Nuclear Medicine and Molecular Imaging
Radiopharmaceutical Chemistry and ApplicationsMedical Imaging Techniques and Applications
Cited by 88
- Verified
A VISION Substudy of Reader Agreement on 68 Ga-PSMA-11 PET/CT Scan Interpretation to Determine Patient Eligibility for 177 Lu-PSMA-617 Radioligand Therapy
Kuo, P. H., Yoo, D. C., Avery, R., Seltzer, M., Calais, J., Nagarajah, J., Weber, W. A., Fendler, W. P., Hofman, M. S., Krause, B. J., et al. (2023) · Journal of Nuclear Medicine
Medical Imaging Techniques and ApplicationsRadiopharmaceutical Chemistry and Applications
Cited by 22
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free